(4R)-4-hydroxy-5-phenylpentanoic acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羟基酸及其衍生物
• 英文名称: (4R)-4-hydroxy-5-phenylpentanoic acid
• 化学式: C₁₁H₁₄O₃
• 分子量: 194.23
• InChiKey: OTIPOAGPXXBSSB-SNVBAGLBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  14
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• Derivatives of 4-hydroxybutanoic acid and of its higher homologue as ligands of $g(g)-hydroxybutyrate (ghb) receptors, pharmaceutical compositions containing same and pharmaceutical uses
  申请人：Bourguignon Jean-Jacques

  公开号：US20050113366A1

  公开（公告）日：2005-05-26

  The invention concerns the field of synthesis organic chemistry applied to the pharmaceutical field and concerns novel derivatives of 4-hydroxybutanoic acid and its higher homologue, 5-hydroxypentanoic acid, their crotonic homologues, pharmaceutical compositions containing them and their pharmaceutical uses. Said novel derivatives are capable of binding with γ-hydroxybutyrate (GHB)-specific receptors and hence capable of exhibiting agonist or antagonist properties, in particular for treating sleep disorders, anxiety and general diseases of the central nervous system. The invention also concerns compounds of general formula (I) wherein the substituents are as defined in the description.

  该发明涉及合成有机化学领域应用于制药领域，涉及4-羟基丁酸及其较高同系物5-羟基戊酸的新颖衍生物，它们的丁烯酸同系物，含有它们的药物组合物以及它们的药用。所述新颖衍生物能够与γ-羟基丁酸盐（GHB）特异性受体结合，因此能够表现出激动剂或拮抗剂特性，特别用于治疗睡眠障碍、焦虑和中枢神经系统的一般疾病。该发明还涉及一般式（I）的化合物，其中取代基如描述中所定义。
• Methods of using norfluoxetine
  申请人：——

  公开号：US20030096019A1

  公开（公告）日：2003-05-22

  The invention encompasses methods of using racemic and enantiomerically pure norfluoxetine, as well as pharmaceutical compositions, pharmaceutical unit dosage forms, and kits comprising racemic and enantiomerically pure norfluoxetine. In particular, the invention encompasses a method of inhibiting or reducing the production of PGE 2 . The invention further encompasses a method of treating or preventing inflammation in a patient, as well as a method of treating or preventing a disease or disorder such as, but not limited to, autoimmune diseases, arthritis, neurologic diseases, inflammatory diseases, fibromyalgia, pain resulting from inflammation, neuropathic pain, and cancer.

  本发明涵盖使用混合型和对映纯的诺氟西泮的方法，以及包含混合型和对映纯的诺氟西泮的药物组合物、药物剂量形式和套装。特别地，本发明涵盖一种抑制或减少PGE2产生的方法。本发明还涵盖一种治疗或预防患者炎症的方法，以及一种治疗或预防自身免疫疾病、关节炎、神经系统疾病、炎症性疾病、纤维肌痛、由炎症引起的疼痛、神经性疼痛和癌症等疾病或紊乱的方法。
• IMMUNE ENHANCEMENT COMPOSITIONS AND USE THEREOF
  申请人：SHOWA DENKO K.K.

  公开号：EP1264600A1

  公开（公告）日：2002-12-11

  Immune enhancement compositions for vaccines for virus, bacteria and/or infectious pathogens which contain stable activity-type antioxidant provitamins; a method of enhancing the immunity of vaccines for virus, bacteria and/or infectious pathogens with use of these compositions; and use of the above composition. As the stable activity-type antioxidant provitamins, at least one compound selected from among L-ascorbic acid derivatives and α-tocopheryl phosphates is used.

  用于病毒、细菌和/或传染性病原体疫苗的免疫增强组合物，其中含有稳定活性型抗氧化剂维生素；使用这些组合物增强病毒、细菌和/或传染性病原体疫苗免疫力的方法；以及上述组合物的用途。作为稳定活性型抗氧化剂维生素，至少使用一种选自 L-抗坏血酸衍生物和 α-生育酚磷酸盐的化合物。
• Immune enhancement compositions and use thereof
  申请人：——

  公开号：US20030035812A1

  公开（公告）日：2003-02-20

  Immune enhancement compositions for vaccines for virus, bacteria and/or infectious pathogens which contain stable activity-type antioxidant provitamins; a method of enhancing the immunity of vaccines for virus, bacteria and/or infectious pathogens with use of these compositions; and use of the above composition. As the stable activity-type antioxident provitamins, at least one compound selected from among L-ascorbic acid derivatives and &agr;-tocopherly phophates is used.

  用于病毒、细菌和/或传染性病原体疫苗的免疫增强组合物，其中含有稳定活性型抗氧化剂维生素；使用这些组合物增强病毒、细菌和/或传染性病原体疫苗免疫力的方法；以及上述组合物的用途。作为稳定活性型抗氧化剂维生素，至少使用一种选自 L-抗坏血酸衍生物和 &agr;-tocopherly phophates 的化合物。